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ABSTRACT 
Porphyria cutanea tarda (PCT) is the most common form of porphyria, diseases 
that arise from decreased activity levels of enzymes in the heme biosynthetic pathway.  
Unlike other porphyrias that are caused by genetic mutations, PCT is often caused by 
exogenous factors, which include alcohol abuse, human immunodeficiency virus (HIV) 
and hepatitis C virus (HCV) infection.  Many studies have shown that there is an overlap 
in the population of patients who have PCT and HCV infection.  HCV infection, in 
particular, causes inflammation and fibrosis in the liver, and disrupts overall homeostasis 
of the body, especially with respect to iron metabolism.  Both diseases present symptoms 
that are either the cause or the effect of iron overloading in the liver. Iron overloading 
leads to oxidative stress in the body which further propagates symptoms of PCT and 
HCV.  This review will investigate the causes, symptoms, and treatment modalities for 
patients with PCT and HCV infection.  It will also evaluate the risk factors, such as iron 
overload and oxidative stress, which may contribute to the overlap among patient 
populations with the two diseases.   
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Hepatitis 
Introduction 
The liver, which is located at the junction of the circulatory system and the 
digestive system, has a vast array of functions.  It processes dietary elements which are 
digested and absorbed in the gastrointestinal tract and synthesizes many important 
molecules and serum proteins, such as coagulation factors and albumin.  The liver also 
participates in the systemic immune response by synthesizing various innate immune 
response-related proteins during early stages in immunological response.  Another 
function of the liver is the detoxification and elimination of endogenous and exogenous 
toxins.  The unique blood supply of the liver results in repeated exposure to foreign 
antigens and toxins so that the liver must continuously distinguish the toxic from non-
toxic material.  The liver provides an effective barrier and protection for the body against 
infections that arise from the gastrointestinal tract.  Because of these functions, the liver 
has a major role in assisting in not only in maintenance of metabolic homeostasis, but 
homeostasis of the body as a whole (Tang et al., 2009). 
Inflammation is a multifaceted interaction between various soluble factors in 
tissues as a response to infection, trauma, autoimmune and toxic injury.  While 
inflammation plays a crucial role in clearing pathogens and healing injured tissues, it can 
also result in tissue damage and loss of function of the tissue or organ.  Inflammation and 
swelling in the liver is called hepatitis; though Hepatitis is a disease that is marked by the 
inflammation and swelling of the liver.  Although not all hepatitis is caused by viral 
infections, many are.  There are two major classes of hepatitis: non-viral and viral 
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hepatitis. Non-viral hepatitis is caused by other factors, such alcohol, toxins and 
autoimmunity.  There are many different types of viral hepatitis with each caused by 
different types of virus (Hall, 2007).   
 
Non-viral Hepatitis 
 Non-viral hepatitis is a class of diseases that is marked by inflammation in the 
liver caused by factors other than viral infection. Autoimmune hepatitis is a non-viral 
hepatitis that is caused by the immune system of the patient and has two types: type 1 and 
type 2. Type 1 can occur at any age, and half the patients also have other autoimmune 
diseases, such as type 1 diabetes and thyroiditis. Type 2 autoimmune hepatitis is the less 
common form which typically affects girls between ages of 2 and 14, and often occurs 
with other autoimmune problems (Mayo Clinic, Autoimmune Hepatitis, 2012). 
Toxins, alcohol in particular, in the body can also cause non-viral hepatitis.  When 
alcohol is processed in the liver and is broken down, it produces harmful chemicals such 
as acetaldehyde, which can trigger inflammation responses in the liver. In the 
inflammation process, healthy hepatocytes are replaced with scars and knots of tissue that 
causes permanent damage in the liver and cause cirrhosis, or liver fibrosis.  Although the 
risk for alcoholic hepatitis increases with the amount of alcohol consumed, the disease 
does not necessarily correlate with it.  Only 35% of heavy long-term drinkers develop 
alcoholic hepatitis, and moderate drinkers may be affected by the disease (Mayo Clinic, 
Alcoholic Hepatitis, 2012). The liver also processes other exogenous substances, such as 
prescription medications and industrial chemicals, which can also create stress in the liver 
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and cause toxic hepatitis. People who either take over-the-counter or prescription drugs 
or have liver diseases have a higher chance of developing toxic hepatitis. Being female is 
another risk factor that is common in alcoholic and toxic hepatitis. Since females 
metabolize toxins more slowly than males do, their bodies are exposed to higher level of 
harmful substances for longer period of time, leading to increased risk of hepatitis (Mayo 
Clinic, Toxic Hepatitis, 2010). 
 
Viral Hepatitis  
There are five types of hepatitis that are caused by viral infection: hepatitis A, B, 
C, D and E.  Viruses are transmitted by the fecal-oral route, perinatally, percutaneously, 
through blood to blood contact, or unprotected intercourse (Hall, 2007). All of the viruses 
cause acute hepatitis, and some, such as hepatitis B, C, and D, can cause chronic 
conditions. Hepatitis A virus (HAV) and Hepatitis E virus (HEV) primarily spread 
through water or food that is contaminated with feces of an infected person. Therefore, 
men who have sex with men and international travelers to developing countries are at a 
higher risk of being infected with the two viruses (National Institute of Health, Viral 
Hepatitis, 2008).  Hepatitis A and E viruses resolve themselves within several weeks to 
several months.  Among patients who have HAV infection, 85% of them will recover 
within three months and the remaining 15% will recover within the next three months. 
HEV has an incubation period of 15-60 days and has a mortality rate of 15-25% among 
pregnant women. Most others who are infected with the virus recover within six weeks 
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after the incubation period (Hall, 2007). Unlike HAV, there is no vaccine for HEV 
(National Institute of Health, Viral Hepatitis, 2008). 
Hepatitis B virus poses a great challenge to the global health care system because 
of the high number of people who are infected with the disease. It is estimated that over 
350 million people are infected with hepatitis B virus (HBV), which can be transmitted 
through blood to blood contact or unprotected sexual intercourse (Hall, 2007). It has an 
incubation period of two to six weeks, after which patients enter the acute phase. 3-5% of 
adults and 95% of children who cannot generate enough immunological response then 
develop a chronic condition (Hall, 2007).  Patients with chronic HBV infection may 
develop cirrhosis, hepatic decompensation, and hepatocellular carcinoma, which is liver 
cancer. Hepatitis D virus (HDV) is similar to HBV since HDV spreads through contact 
with infected blood and unprotected sexual contact. However, HDV can only infect 
patients who have concurrent HBV infection.  Injection drug users and those who have 
received blood transfusion before 1987 are among those who have the highest risk.  Since 
there is no vaccine for HDV, one of the best ways to prevent HDV infection is to avoid 
risk factors, such as using contaminated needles and razors.  Since only those with HBV 
infection can be infected with HDV and there is a vaccine for the former, those who do 
not have HBV infection should receive vaccination (National Health Institute, Viral 
Hepatitis, 2008). 
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Hepatitis C Virus 
The last of the viral hepatitis is called hepatitis C, which is caused by hepatitis C 
virus. It was first discovered in 1975 in post-transfusion hepatitis patients, and was 
named NANBH, or non-A non-B hepatitis.  Like HBV infection, HCV infection and its 
associated liver complications have become a major challenge in the global health system.  
Since its discovery, the number of infections has grown steadily and it is estimated that 
170 million worldwide has chronic HCV infection, which is about 3% of the world’s 
population; approximately 3.2 million people in the US have chronic HCV infection and 
17,000 new HCV cases each year in the US (Center for Disease Control and Prevention, 
Hepatitis C, 2012). 
Much research has been done on HCV and it is now known that the disease is 
genetically heterogeneous with six major genotypes, and each genotype has varying 
prevalence in different geographic regions (Simmonds et al., 1992). The following list 
pairs a genotype and the region where it is the most prevalent.  
1a- North and South America 
1b- South America, Europe and Asia 
2- Europe, South Africa and Japan 
3- Australia, South Asia and South America 
4- Egypt and Middle East 
5- South Africa and Southeast Asia 
6- Southeast Asia 
7, 8, 9- Southeast Asia (Zein, 2000) 
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HCV is transmitted both parenterally and perinatally, and is cleared 
spontaneously in 20% of the cases, with the other 80% developing chronic hepatitis C 
infection.  About 20% of the chronically infected patients eventually sustain permanent 
liver damage and fibrosis, and 4% develop hepatocellular carcinoma (Schuppan et al., 
2003).  Currently there is no vaccine for HCV, and its associated complications are the 
leading cause of liver transplantation in the US and Europe (Wald, 2007). 
A positive strand RNA virus of the Flavivirdae family, HCV contains a single-
stranded RNA genome that has approximately 9600 nucleotides.  This RNA is a template 
for both mRNA transcription and RNA replication (Tang, 2000).  HCV RNA encodes a 
single protein, which is then processed to give rise to ten structural and nonstructural 
proteins.  Nonstructural proteins, which are named p7, NS2, NS3, NS4A, NS4B, NS5A, 
and NS5B, form an HCV replicase that is located on the membrane of endoplasmic 
reticulum.  Structural proteins, such as core, E1, and E2 form the viral particles (Jeong, 
2012). 
 
Diagnosis 
The range of the incubation period of HCV is 3-20 weeks with the mean period 
being seven weeks, and antibodies can be detected as early as a week after the infection 
(Center for Disease Control, ABC’s of hepatitis, 2012).  The infection and disease 
progress can be divided into acute and chronic phases.  The former refers to period of 
time immediately after infection and can last from 3- 24 weeks and usually less than six 
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months.  The majority of the patients with HCV infection develop a chronic condition as 
they are not able to eliminate the virus spontaneously.   
There are many ways to evaluate whether or not a patient has been infected with 
HCV.  The first method is to look carefully into the health history and determine the 
presence of risk factors.  People who may be at risk for contracting hepatitis C are those 
who have been on long-term kidney dialysis or have received blood, blood products or 
organs from a donor who has hepatitis C.  Sharing needles with others who have hepatitis 
C is a big risk factor as well.  It is debated whether or not having unprotected sexual 
contact with those with hepatitis C is another risk factor as those sexual contacts may be a 
result of other risk factors.  Babies who are born to mothers with the disease are at a 
higher risk as well (National Institute of Health, Viral Hepatitis, 2008).     
One of the tests that can be used to screen for liver disorders is the Liver Function 
Test (LFT).  LFT evaluates the concentrations of liver alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), gamma- glutamyltransferase (GGT), and alkaline 
phosphatase (ALP).  The normal values of these enzymes in males are as follows: ALT 
(7-55 u/L), AST (8-48 u/L), GGT (9-48 u/L), ALP (45-115 u/L), albumin (3.5-5.0 g/dL), 
and total protein (6.3-7.9g/dL) (Mayo Clinic, Live Function Test, 2012). 
There are two major classes of assays that are used to diagnose HCV infection.  
One is a serologic assay that identifies antibodies that are specific to HCV (anti-HCV) in 
the serum or plasma.  The other is a molecular assay that directly detects HCV RNA, and 
polymerase chain reaction (PCR) has been incorporated recently to these assays to 
increase the sensitivity of the tests (McOmish et al., 1994; Ghany et al., 2009). 
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The diagnosis of HCV usually requires a positive test for both anti-HCV 
antibodies and HCV RNA.  One of the goals of the diagnosis process is to differentiate 
between acute and chronic HCV, and different diagnosis is made depending on the results 
of the two tests as shown in table 1 (Ghany, 2009). 
Table 1 – Interpretation of anti-HCV and HCV RNA diagnostic exams (Table 
amended from Ghany et al. 2009) 
Anti-HCV HCV RNA Interpretation 
Positive Positive Acute or chronic HCV depending on the 
clinical context 
Positive Negative Resolution of HCV; acute HCV during period 
of low-level viremia 
Negative Positive Early acute HCV infections; chronic HCV in 
setting of immunosuppressed state; false 
positive HCV RNA test 
Negative Negative Absence of HCV infection 
 
Liver biopsy is a useful tool in monitoring chronic HCV progression.  It provides 
information on the extent of the liver injury and if the patient needs to be aware of the 
risk of developing HCC.  The biopsy is given a grade using one of the common staging 
systems used for evaluating the fibrosis or cirrhosis in liver which is shown in table 2 
(Kleiner et al., 2005). Although the staging systems differ from one another, cirrhosis is 
the last stage, during which liver damage can cause other serious complications. 
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Knodell et al, 
1981 
Scheuer, 1991 METAVIR, 1994 Batts and 
Ludwig, 
1995 
Ishak et al, 1995 
 
0: No fibrosis 0: None 0: No fibrosis 0: No 
fibrosis 
0: No fibrosis                
1: Fibrous 
portal 
expansion 
1: Enlarged, 
fibrotic portal 
tracts 
1: Stellate 
enlargement of 
portal tracts 
without septae 
formation 
1: Portal 
fibrosis 
1: Fibrous expansion of 
some portal areas, with 
or without short fibrous 
septa 
               
   2: 
Periportal 
fibrosis 
2: Fibrous expansion of 
most portal areas, with 
or without short septa 
               
3: Bridging 
fibrosis 
(portal-portal 
or portal-
central 
linkage) 
2: Periportal or 
portal-portal 
septa but intact 
architecture 
2: Enlargement of 
portal tracts with 
rare septae 
formation 
3: Septal 
fibrosis 
3: Fibrous expansion of 
most portal areas with 
occasional portal to 
portal bridging 
               
 3: Fibrosis with 
architectural 
distortion but no 
obvious cirrhosis 
3: Numerous 
septae without 
cirrhosis 
 4: Fibrous expansion of 
portal areas with 
marked bridging (portal 
to portal as well as 
portal to central) 
               
4: Cirrhosis 4: Probable or 
definite cirrhosis 
4: Cirrhosis 4: 
Cirrhosis 
5: Marked bridging 
with occasional nodules 
(incomplete cirrhosis) 
               
    6: Cirrhosis, probable 
or definite 
               
 
Symptoms 
Most people who are recently infected with HCV do not show any symptoms, but 
only about 10-20% of them develop jaundice and other nonspecific symptoms such as 
Table 2 – Comparison of Commonly Used Staging Systems for Chronic Hepatitis C 
(Table amended from Kleiner et al., 2005) 
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fatigue and nausea (Caballes et al., 2012).  About 80% of patients who contract HCV 
develop a long-term, or chronic, infection (Hall, 2007). Although there are no symptoms 
in early stages, if the infection is present for many years, the liver may develop 
inflammation which then leads to fibrosis in the liver, which is also called cirrhosis.  
Some of the tissue may be damaged due to HCV, but persistent inflammation leads to 
proliferation of fibroblasts and epithelial cells.  This may lead to loss of function in these 
tissues, leading to decreased overall efficiency of the liver.  Some symptoms that result 
from loss of liver tissues are abdominal pain, abdominal swelling, fatigue, fever and 
vomiting.  In some cases, red blood cells and heme cannot be broken down and excreted 
normally, leading to the accumulation of bilirubin in the body and jaundice, or yellowing 
of skin (National Institute of Health, Hepatitis C, 2011). 
Inflammation and proliferation of certain cells may lead to selection of cells that 
are at higher risk of malignant transformation.  In 4% of the cases, this process leads to 
the development of hepatocellular carcinoma (Wald et al., 2007).  There are a few HCV 
proteins that have been shown to change the regulation of the cellular proliferation 
process.  HCV core proteins, which are coded by the C region of the HCV genome, use 
many different mechanisms to induce oncogenesis, such as inhibition of apoptosis and 
stimulation of growth factors and their respective receptors.  They also activate 
transcription factors/proto-oncogenes and alter the tumor suppressor gene p53.  
NS(nonstructural protein)3 and NS5A interact with it to lower the rate of apoptosis.   
HCV also attacks another tumor suppressor gene named pRb.  Two specific 
proteins, core and NS5B in particular, have been shown to reduce the concentration of 
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pRb in liver cells.  NS5B directly interacts with the tumor suppressor to attract E3 
ubiquitin ligase E6AP (E6-associated protein), which degrades pRb.  This then 
contributes to uncontrolled proliferation of cells and cancer (Jeong et al., 2012). 
 
Life cycle of HCV 
HCV infects the liver in vivo, and it uses certain attachment and entry factors to 
cross the hepatocyte cell membrane and to release its RNA in the cell.  The HCV genome 
is a single stranded RNA with 9600 nucleotides which acts as a template for RNA 
replication and translation.  The polyprotein which is synthesized by translation is 
modified both co-translationally and post-translationally.  Processed viral polyprotein is 
assembled into new virions and is released by the host cell.   
Although the exact mechanism for HCV assembly is still being researched, most 
agree that HCV replication takes place in the host cell, and the virus is exocytosed after it 
is made into a complex with VLDLs (Very Low Density Lipoprotein) in chronic HCV 
patients (Tang et al., 2009).  As shown in figure 2, it is also thought that NSs are divided 
into two pools in the infected cells.  One participates in the replication process and is 
incorporated into the RC, whereas the other is involved in particle assembly (Tang et al., 
2009).   
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Figure 1 – Mechanism of HCV using apolipoproteins and VLDL (Figure taken from 
Tang et al., 2009) 
 
HCV utilizes receptor mediated endocytosis to enter host cells, and this requires 
coordination of different receptors such as LDL-R (low density lipoprotein receptor), 
GAG (glycosaminoglycans or heparin sulfate) and CD81.  Once the initial interaction is 
established between HCV and GAG and LDL-R, CD31 binds to the virus to allow entry 
into the cell as demonstrated in figure 1 (National Institute of Health, 2006). 
After HCV enters the cell, it undergoes translation and RNA replication to infect 
the cell and create new virions.  Eukaryotic translation is normally initiated when the 
mRNA 5’- cap recruits eIF4F (eukaryotic initiation factor 4F) and the 40 S ribosomal 
subunit binds to the 5’ end and scans for a start codon.  Since the HCV RNA does not 
contain a 5’-cap, it must use an alternate way to initiate protein translation in an IRES 
(internal ribosome entry site)-based cap-independent approach.  RNA replication takes 
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place in a replication complex, where NS’s are anchored to intracellular membranes, 
using RNA replicase. 
 
Figure 2 – Entry of HCV into the Target Cell Initiates the Infection Process (Figure 
taken from Tang et al., 2009) 
 
 
 
Prevention and treatment 
There is no vaccine for hepatitis C, so the only way to prevent infection is to 
avoid the risk factors.  The goal of treatments used for HCV is to reduce or eliminate 
virus from the circulatory system in order to slow the progression of the disease.  This 
means to reduce the risk of cirrhosis and complications that may result from this, such as 
lowered liver functions and development of HCC.  Many patients are given antiviral 
medications such as pegylated interferon alpha and ribavirin; the former is injected 
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weekly and the latter is taken orally twice a day.  Each genotype responds differently to 
treatments, and patients with genotype 1 are given newer drugs such as telaprevir and 
boceprevir because it is the least responsive to medications (Zeuzum et al., 2008; 
National Institute of Health.  Hepatitis C, 2011; Naggie, 2012). In patients that have liver 
fibrosis, the chance of development of hepatocellular carcinoma may be reduced by a 
fifth if they respond well to anti-HCV interferon therapy (Tang et al., 2009).  If patients 
develop cirrhosis or hepatocellular carcinoma, they may require a liver transplant.   
 
Porphyria 
Introduction 
The circulatory system is present in every organism, and its main function is to 
transport nutrients and waste.  In humans, the circulatory system transports oxygen from 
the lungs to all the tissues of the body, and carbon dioxide from the tissues to the lungs.  
Since oxygen is not highly soluble in water and dissolved oxygen cannot meet the 
demands of human body, it utilizes a certain type of hemoprotein to carry oxygen 
(National Institute of Health.  Oxygen transport, 2011). 
All hemoproteins contain a heme molecule, which is ubiquitous in all living 
organisms, and an apoprotein. Heme is synthesized from simple molecules such as 
succinyl-Coenzyme A (CoA) and glycine.  An enzyme called aminolevulinic acid 
synthetase combines the two compounds to make aminolevulinic acid (ALA), and eight 
ALAs are used to make protein the porphyrin part of the heme.  On the last step of the 
heme biosynthetic pathway, iron ion is fixed on the four nitrogen atoms that are located at 
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the center of the heme (Champe, 2008).  Heme is poorly soluble in water so it is 
associated with apoproteins, which then forms hemoproteins.  There are many types of 
hemoproteins such as myoglobins, hemoglobin, and cytochrome c, b, a.  (Li et al., 2011)  
Heme has many functions in transportation and storage of diatomic gas and 
electron transfer in myoglobin, hemoglobin and cytochrome c.  There are several 
different types of heme but heme b and heme c are the two most common forms, which 
are shown in figure 3.  Heme b interacts with apoprotein noncovalently and is used in 
hemoglobin and myoglobin.  Heme c interacts with apoprotein covalently between heme 
vinyl and cysteine residues of the apoprotein, and is used in the cytochrome c complex.  
The function of the heme protein is affected by many variables such as the 
microenvironment of the proteins and solvent accessibility to heme (Li et al., 2011). 
 
 
Figure 3 – Structures of Heme B and Heme C. Heme b interacts with apoproteins 
noncovalently whereas heme c covalently. Heme c forms a covalent bond with the sulfur 
group on cysteine (Figure taken from Li et al., 2011) 
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The human circulatory system utilizes hemoglobin (Hb), one of the heme b 
hemoproteins, to carry oxygen from the lungs to the tissues.  The normal range of Hb in 
males is 13.8 to 17.2 g/dL and in females 12.1 to 15.1 g/dL (Medline Plus, 2013).  Hb has 
two pairs of subunits named alpha and beta chains.  Alpha and beta chains have two 
forms which are taut (T) and relaxed (R); the former refers to the configuration of 
hemoglobin when it has oxygen to it and the latter when it is not.  Hb has the unique 
property where all four subunits interact with one another; when one binds to an oxygen 
molecule, the others are more likely to bind an oxygen molecule as well.  Equally, when 
one of the subunits drop off the oxygen molecule, the others are more likely to do the 
same.  This is often referred to as ‘cooperative binding’ (Freeman, 2008).  
  
 
Figure 4 – The saturation curve of Hb under standard conditions T=37 , pH= 7.4 
and     = 40mm Hg (Figure taken from National Institute of Health at 
http://www.ncbi.nlm.nih.gov/books/NBK54103/) 
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Cooperative binding induces an allosteric effect where relationship between the 
partial pressure of oxygen and percent saturation of Hb is a sigmoid curve. At low    or 
high     the curve has a small slope whereas the middle of the saturation curve between 
20-80% of the curve is much steeper. This unusual cooperative binding maximizes the 
ability of Hb to bind to molecular oxygen at high partial pressure and unbind at low 
partial pressure.  Figure 4 is the saturation curve of Hb at standard physiological 
conditions under which body temperature is 37 , pH is 7.4 and     is 40mm Hg (NIH, 
oxygen transport, 2011). 
The following equation describes the Hb oxygen saturation curve, where     
gives the fraction of the Hb that is bound to oxygen: 
     
         
 
           
 
 
The term n is Hill’s coefficient, which is 2.7 for human adult Hb, and     is the partial 
pressure of oxygen at which half the Hb is saturated.   
Hb saturation curve has other variables that can shift it such as temperature, pH, 
     and 2, 3-DPG.  The affinity of Hb for oxygen gets lower as the curve moves to the 
right and high as it moves to the left (NIH, oxygen transport, 2011), and these changes 
mainly take place to compensate for the changes that impacts the variables. For example, 
a person’s temperature will increase and pH decrease when a person is exercising 
intensely. This means that the body is in need for more oxygen, and the affinity of Hb for 
oxygen will fall under these conditions.  Increase in temperature and decrease in pH 
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shifts the Hb oxygen affinity curve to the right as it is shown in figure 5 and 6, and will 
help Hb deliver oxygen more efficiently to the tissues. 
 
 
Figure 5 – The effect temperature on the saturation curve of Hb. 
(Figure taken from National Institute of Health at 
http://www.ncbi.nlm.nih.gov/books/NBK54103/) 
 
Figure 6 – The effect of pH on Hb saturation curve. 
(Figure taken from National Institute of Health at 
http://www.ncbi.nlm.nih.gov/books/NBK54103/) 
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Classification of porphyrias 
There are eight steps in the heme biosynthetic pathway and eight enzymes to 
carry out each step.  Porphyria refers to a group of eight diseases that can arise in 
individuals with genetic disposition that causes mutations in the enzymes or risk factors 
that reduce the level of enzyme activity.  The heme biosynthetic pathway regulates itself, 
so the reduction of enzyme activity in any particular step leads to deregulation of the 
pathway and overproduction of heme precursors (Lambrecht et al., 2007).  Figure 7 
shows the eight enzymes in the heme biosynthesis pathway, and corresponding 
porphyrias that arise when activity level of any one them is lowered.  
 
 
Figure 7 – Pathway of heme biosynthesis and classification of porphyria based on 
reduced activity level or deficiencies present in each enzyme (Figure taken from Frank 
et al., 2010) 
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Different standards may be used to classify porphyrias.  One of the common ways 
is to group them by the site of overproduction of heme precursors.  By this criterion, 
porphyrias can be divided into either hepatic porphyria, which results because of 
porphyrin precursors made in the liver, or erythropoietic, in which excess porphyrin 
production occurs in bone marrow erythroid cells (Balwani et al., 2012).  Porphyrias can 
also be separated by the symptoms that it presents.  Cutaneous porphyrias can cause 
accumulation of porphyrin in the skin, hepatocytes, and red blood cells.  These 
accumulations can cause pathophysiological symptoms that are mostly confined to the 
skin where sunlight will cause built up porphyrins in the skin to react, leading to blisters 
and scars.  Acute porphyrias, on the other hand, affect different parts of the body from 
cutaneous porphyrias.  Their symptoms include abdominal pain, weakness, dementia, and 
hallucinations.  Most patients who have porphyria exhibit symptoms that is typical to 
either cutaneous or acute porphyrias, but some who have hereditary coproporphyria 
(HCP) and variegate porphyria (VP) may present both (American Porphyria Foundation, 
2010). Acute hepatic porphyrias refer to autosomal dominant porphyrias such as Acute 
Intermittent Porphyria (AIP), HCP, VP and autosomal recessive ALA-dehydratase- 
deficient porphyria (ADP). 
Porphyrias are rare diseases that affect a small percentage of the population.  It is 
estimated that less than 200,000 people in the US suffer from porphyria, which is about 1 
in 1,500.  In Europe, the most common type of porphyria, porphyria cutanea tarda, affects 
about 1 in 10,000 people and the most common acute porphyria, AIP, 1 in 20,000  
(American Porphyria Foundation, 2010). 
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Porphyria Cutanea Tarda 
The most common form of porphyria is called Porphyria Cutanea Tarda (PCT).  
PCT is a cutaneous porphyria that is caused by defect or lowered activity level of 
uroporphyrinogen decarboxylase (UROD) (American Porphyria Foundation, 2010).  
UROD is the enzyme that is responsible for the conversion of uroporphyrinogen III to 
coproporphyrinogen III by decarboxylation of four carbon dioxide molecules (Phillips et 
al., 2001).  PCT is a complex disease which has multigenetic predisposition, and 
environmental risk factors are necessary for clinical symptoms to surface.  The risk 
factors that can trigger PCT are HCV and human immunodeficiency virus (HIV) 
infections, alcohol abuse, estrogen therapy and mutations in hemochromatosis (HFE) 
genotypes (Frank et al., 2010).  Symptoms develop when residual and hepatic UROD 
decreases below a threshold of 25%.   
The symptoms manifest themselves on mainly the skin, where photoreactive 
porphyrins can lead to blistering and scarring.  Other symptoms include hepatic 
accumulation and urinary excretion of uroporphyrins, altered iron indices, and hepatic 
iron overload (Panton et al, 2013).   
PCT is categorized into two subtypes: hereditary PCT (fPCT) and sporadic PCT 
(sPCT).  About 25% of total PCT patients have a genetic disposition that causes 
mutations in UROD, which then causes the reduced activity level of fPCT.  This alone is 
usually not enough but must be accompanied by external risk factors for clinical 
symptoms to manifest.  The majority of the remaining 75% of PCT patients present with 
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the sporadic form of the disease.  They do not have mutations in UROD locus, and the 
pathogenesis of the disease is multifactorial (Aarsand et al., 2009). 
 
fPCT 
fPCT is caused by mutations in UROD gene which is an autosomal dominant 
disease with low penetrance.  UROD cDNA was discovered in 1986 to have an ORF 
(open reading frame) of 1,104 nucleotides which is a template for polypeptide that is 367 
amino acids long (Roméo et al., 1986).  This enzyme has a homodimeric structure and 
has one active site where the carboxylic groups on uroporphyrinogen III are removed to 
convert it to coproporphyrinogen III (Roméo et al., 1986).  There are currently 30 
mutations on UROD locus that has been reported and they are listed in table 3 along with 
the hypothesized effect of the mutation on UROD structure. 20 of them are missense 
mutation, and the other 10 are mutations that are either nonsense or cause alternative 
splicing site, and the latter effect tends to be more detrimental than the former (Phillips, 
2001). 
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Table 3 – Structural location and the probable effect of the reported missense 
mutations in UROD (Table amended from Phillips et al., 2001) 
 
Residue  
Change 
Structural  
location Probable effect of mutation  
 
G25E H1-S2 Tight turn, restricted main chain  
P62L HC-H1 Residue within disordered loop, unknown function or effect of mutation  
A80S/G S2 No explanation  
V134Q H2 Polar residue into a hydrophobic pocket  
R144P H2 Salt bridge between R144 and Q63, helix-helix stability; P is also a helix breaker  
G156D S3-HG Tight turn and restricted side-chain access  
M165R HG Charged residue inserted into a hydrophobic pocket  
E167K  HG Charge reversal and the E167 links residues in a surface loop  
G168R HG-HH Tight turn, restricted main chain  
R193P H3 Pro insertion into middle of helix  
L195F H3 No explanation  
L216Q S4 Hydrophilic residue placed into hydrophobic core, near active site  
E218K S4 Charge reversal and longer side chain, near active site  
H220P  S4-HI Histidine links residues in the intersection of several loops, proline is rigid and 
hydrophobic  
F229L  H4 No explanation  
F232L  H4 No explanation  
L253Q H4-S5 No explanation  
I260T S5 No explanation, water molecule replaces extra carbon atom  
G281E/V S6 Mutant side chain protrudes into active site cleft  
L282R  S6 Charged residue inserted into a hydrophobic pocket, near active site  
R292G  H6 Arginine forms a salt bridge between H6 and S8  
G303S S7 Gly in conformationally strained conformation, side-chain conflicts  
N304K  S2 Tightly packed between H6 and H7, no room for longer Lys chain  
Y311C
*
 HJ Tyrosine packs against Arg179 side chain not supported by Cys, at dimer interface  
G318R  H7 Glycine lies on an internal turn of helix, large side chains disrupt packing  
M324T  H7 Side chain points toward protein disrupts packing of helix, dimer interface  
R332H S8 No explanation  
I334T S8 No explanation 
*
On the dimer interface.   
Within 0.7 to 1.2 nm of the dimer interface.   
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sPCT 
For patients with sPCT, UROD activity is reduced only in the hepatocytes 
because it is an acquired disease.  Thus far, no UROD mutations have been detected in 
sPCT patients.  Since patients with fPCT and sPCT present the same clinical symptoms 
with the same risk factors, it is necessary to use other methods to distinguish them.  One 
of the most common strategies used to distinguish the two subtypes of PCT is to measure 
the UROD activity level in erythrocytes (Balwani et al., 2012).  Another method that is 
used is to measure the level of isocoproporphyrin, which also accumulates along with 
uroporphyrinogen III in sPCT patients (Tarwater et al., 2008). 
 
Symptoms and Diagnosis 
Like other cutaneous porphyrias, the symptoms of PCT are mostly confined to the 
skin.  Photosensitive porphyrins accumulate in the skin, and they can be exposed to light 
in the UV range, which excites the molecules.  Porphyrins reach a high energy state and 
release the excess energy as fluorescence by forming single oxygen as well as other 
species that causes damage to the skin in the form of blisters and scars.  (Tarwater et al., 
2008) Increased hair growth as well as darkening and thickening of the skin are other 
common symptoms of PCT, but neurological or abdominal complications are not usually 
associated with the disease.  Mild liver abnormalities are common among PCT patients.  
However, in rare cases, PCT may lead to more serious complications such as cirrhosis 
and cause permanent liver damage (Lee et al., 2010).  It has been noted that many PCT 
patients have HCV infection, although the reverse does not hold true.   
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One commonly used exam to screen for PCT is to measure the total porphyrin 
levels in the plasma.  This test is sensitive and specific for cutaneous porphyrias, and also 
helps to differentiate PCT from Variegate Porphyria (VP), which arises when 
protoporphyrinogen oxidase is either defective or exhibits lowered activity levels.  Along 
with this test, investigating the patterns of porphyrins in wastes may confirm the 
diagnosis.  Urine has mostly uroporphyrin and 7-carboxylate porphyrins, and feces 
contain isocoproporphyrin.  As it is demonstrated in table 4, increases in porphyria 
cutanea tarda can increase the uroporphyrin, coproporphyrin and protoporphyrin levels in 
urine, stool, erythrocytes and plasma (Tarwater, 2008). 
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Table 4 – Characteristic level of biochemical substances present in urine stool and 
blood in the presence of PCT and hepatoerythropoietic porphyria (Table amended 
from Frank et al., 2010) 
+ = slightly increased; ++ = moderately increased; +++ = highly increased; ++++ = very 
increased 
Urine uroporphyrin coproporphyrin protoporphyrin 
Porphyria Cutanea 
Tarda 
++++ ++ normal 
hepatoerythropoietic 
porphyria 
++++ Isocopropo normal 
    
Stool uroporphyrin coproporphyrin protoporphyrin 
Porphyria Cutanea 
Tarda 
++ Isocopropo +++ 
hepatoerythropoietic 
porphyria 
normal Isocopropo normal 
    
Blood/erythrocytes uroporphyrin coproporphyrin protoporphyrin 
Porphyria Cutanea 
Tarda 
normal normal normal 
hepatoerythropoietic 
porphyria 
normal + ++++ 
    
Blood/plasma uroporphyrin   
Porphyria Cutanea 
Tarda 
++   
hepatoerythropoietic 
porphyria 
++   
 
Treatment 
Treatment for PCT is targeted to different facets of the disease.  In order to 
prevent skin damage, protective clothing and sunscreen should be worn to minimize 
exposure to sunlight.  Since PCT is caused in large part because of risk factors, patients 
should avoid them by discontinuing any estrogen therapy as well as alcohol use.  There 
are many protocols for phlebotomy, but one is to remove 300ml every week or 500ml 
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blood every two weeks over a three to six months period.  Although this resolves certain 
skin problems within several months, it can also induce anemia which should be avoided.   
Chloroquine is hypothesized reduce the photosensitivity of skin by inhibiting 
biosynthesis of porphyrins and increasing the rate of their secretion (Frank et al., 2010).  
Therefore, chlorquine is often used in PCT therapy and remission can be expected after 
6-9 months of a 125mg dose twice a week (Frank et al., 2010). 
 
Iron and Reactive Oxygen Species 
The relationship between PCT and HCV has not been definitively established, but 
there are evidences that support strong relationship between the two diseases (Gisbert et 
al., 2003). Since HCV is a more widespread disease than PCT, the percentage of HCV 
patients who suffer from PCT is significantly lower than that of PCT patients who suffer 
from HCV.  The majority of HCV patients do not suffer from PCT, but it has been shown 
that about 47% to 50% of PCT patients suffer from HCV (Gisbert et al., 2003).  It is 
thought that HCV leads to fibrosis in the liver and iron overload.  Iron generates reactive 
oxygen species (ROS) which can damage tissues and organs. 
 
Iron metabolism 
Iron makes up 32% of the total mass of the earth (Von Drygalski et al., 2012), and 
has many important functions in mammals as it helps Hb deliver oxygen from the lungs 
to the tissues.  Because of its highly reactive property that can damage cells and tissues, 
iron absorption and transport must be tightly regulated.  Iron balance is achieved mainly 
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by absorption because mammals cannot regulate iron excretion.  A normal adult has 3-4 g 
of iron distributed and stored in several different places.  Approximately 3mg of iron is 
stored in transferrin pool and 300mg in the myoglobin pool (Von Drygalski et al., 2012).  
The tissue pool, in which liver plays a large role, stores about 200mg in females and 1g in 
males.  2000mg of iron is bound to heme in red blood cells and is used to carry oxygen.   
Red blood cells (RBC) in humans have an average life span of 120 days, so 
approximately 1% of the total amount must be replaced daily.  An average adult has 
about 1500 to 2000mL of RBC, which means 15mL to 20mL must be turned over each 
day; each milliliter of RBC contains 1mg of iron, so the body needs 15-20mg of 
elemental iron to replace the RBC’s.  The majority of the iron that is present in plasma 
and used in heme biosynthesis is derived from the breakdown of erythrocytes in 
macrophages, but some is absorbed through diet (Anderson et al., 2012). 
 
Iron recycling process 
Erythrocytes are taken up and processed by resident macrophages in the liver and 
the spleen.  Once endocytosed by macrophages, RBC’s in erythrocytes are break down 
the hemoglobin into globin and heme moieties.  The former part is further broken down 
to individual amino acids.  The iron in heme is dissociated and is exported through 
ferroportin.  It then forms a complex with transferrin to be transported to the bone 
marrow to be recycled.  This recycling process is very efficient and close to 80-90% of 
iron is reused in heme biosynthetic pathway.  The other 10-20% of iron is stored in the 
macrophage as ferritin (Von Drygalski et al., 2012). 
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Iron absorption in diet 
Iron that is obtained through diet must be solublized before it can be absorbed by 
intestinal epithelial cells, which are also called enterocytes (Fuqua et al., 2012).  The low 
pH in the stomach achieves this and keeps the iron in the ferric (    ) state so that it can 
be absorbed in the proximal small intestine.  At the surface of the absorptive cells, the 
iron encounters DcytB (duodenal cytochrome B) and other reductases, which reduce the 
ferric to ferrous (    ) state.  DMT-1 (divalent metal-ion transporter 1, which is also 
named Nramp2 [natural resistance-associated macrophage protein family 2]) carries the 
ferrous iron into the enterocyte.  Although the mechanism for the absorption of heme iron 
is not understood, it is generally thought that it is absorbed about 5 to 10 times better than 
elemental iron.  Once it is in the cell, it follows one of two paths depending on the iron 
concentration in the body.  If the concentration is high, iron forms a complex with 
apoferritin to make ferritin, which is then stored in the cell.  If the concentration is low, it 
is transported to the basolateral membrane of the enterocyte to be carried out by 
ferroportin (Fpn1), which is the only known iron export protein in mammalian cells.  
Enterocytes that are further down in the gastrointestinal tract have decreasing amount of 
ferroportin (Anderson et al., 2009). 
Once ferrous iron is in the circulation, it undergoes another change in oxidation 
state by ferroxidase from the ferrous (    ) to ferric state (    ) as shown in figure 8.  
Iron in the ferric state is required in order to be carried by transferrin, which is a major 
iron transport protein in the circulation.  Transferrin can bind up to two iron atoms and 
thus has three different states.  Transferrin that is bound to two iron atom is called diferric 
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transferrin, one monoferric transferrin and none apotransferrin.  Transferrin attaches itself 
to TfR1 (transferrin receptor 1) in the bone marrow to be endocytosed using clathrin-
coated pits.  The concentration of TfR1 is the highest in erythroid cells and varies 
depending on the stage that the cell is in the erythrocyte maturation process.  The affinity 
of transferrin for TfR1 varies with the number of attached iron atoms; diferric transferrin 
is seven times more likely to bind to TfR1 than monoferric transferrin and a thousand 
times more likely than apotransferrin (Von Drygalski et al., 2012).  Once transferrin is in 
the immature erythrocytes, they are brought to endosomes.  Proton pumps on endosomes 
generate low pH which causes transferrin to release the iron atoms into the cytosol.  An 
endosomal ferrireductase named Steap3 changes the oxidation state of iron once again 
from ferric state (    ) to ferrous (    ), and all iron atoms are brought to the 
mitochondria to be fixed onto heme in the last step of the heme biosynthetic pathway 
(Anderson et al., 2005; Von Drygalski et al., 2012) 
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Figure 8 – Schematic of path of dietary iron during absorption into enterocytes and 
transport via transferrin (Figure taken from Gisbert et al., 2003) 
 
Regulation of iron uptake 
Hepcidin is a molecule that is 25 amino acids long and is synthesized in the liver 
to maintain iron homeostasis.  It binds to the ferroportin which is on the surface of 
enterocytes, and causes it to be degraded after it is endocytosed; this prevents the cells 
from taking up dietary iron.  Hepcidin also causes the iron from the enterocytes to be 
exported, thus effectively trapping iron in the cells.  This then leads to the decrease of 
serum iron concentration (Nemeth et al., 2004). 
There are many factors that influence the rate of hepcidin synthesis.  Hypoxia 
leads to an increase in erythropoiesis, and since iron is used to make hemoglobin, it will 
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eventually reduce hepcidin concentration.  Decreased hepcidin concentrations will 
increase the amount of ferroportin leading to elevated dietary iron absorption (Anderson 
et al., 2009).  High iron stores and inflammation are known to increase hepcidin 
concentration and iron absorption.  The former is also associated with increased levels of 
transferrin and soluble TfR1 protein.  Inflammatory signals such as interleukin (IL)-6 
have been experimentally shown to increase hepcidin level in urine (Drygalski et al., 
2012). Although the mechanism by which the body detects iron concentration is poorly 
understood, it is hypothesized that the concentration of diferric Tf may serve as an 
important signal (Anderson et al., 2005). 
 
Role of iron in the body 
Iron is an important element that has many functions in the body.  It is a cofactor 
in many reactions such DNA synthesis where iron has a crucial part in reduction of 
ribonucleotides to their corresponding deoxyribonucleotides.  It also participates in host 
defense and in metabolism.  In the case of excess iron, which is called iron overload, 
highly reactive properties of the element can damage cell membranes, proteins and DNA. 
One of the ways to measure iron in the body is to evaluate the concentration of ferritin, 
which increases with excess iron in the body.  The normal range of ferritin in the blood is 
20-200ng/ml; at ferritin levels exceeding 1000ng/ml, one is considered to have iron 
overload.  However, the majority of complications that can arise from the condition can 
be avoided at levels below 1500ng/ml.  Skin is one of the most vulnerable parts of the 
body to ROS because there is an abundance of polyunsaturated fatty acids, which is 
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particularly reactive with ROS, and its constant exposure to high level of oxygen 
concentration and ultraviolet (UV) rays (Lambing et al., 2012). 
Iron can cause damage to the body by generating reactive oxygen species, which 
are free radicals.  Free radicals are chemical species that have an open electron shell or 
unpaired valence electrons.  They are formed when there is enough energy and a covalent 
bond between two chemical species is cleaved.  Balanced dissociation between them is 
called homolysis, and unequal cleavage is called heterolysis.  Unpaired valence electrons 
on free radicals make it reactive, and cause them to dimerize or polymerize 
spontaneously.   
Free radicals are generated when foreign antigens enter the body and attract 
macrophages.  As the phagocytes process the antigens after phagocytizing the antigens, 
activation of NAD(P)H (nicotinamide adenine dinucleotide/ nicotinamide adenine 
dinucleotide phosphate) oxidase cytochrome b occurs.  This increases NAD(P)H while 
producing superoxide (  
  ) using an oxidative burst.  Oxidative burst play a crucial role 
in immunology as it helps the phagocytes to degrade foreign antigens.  At physiological 
pH, superoxide that is synthesized will spontaneously lead to production of hydrogen 
peroxide (    ) using superoxide dismutase (SOD) as a catalyst.   
   
      
          
Free radicals can be generated when superoxide radicals (  
 ) react with hydrogen 
peroxide to produce ROS.   
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Studies have shown that the two reactants of the above equation, superoxide radicals and 
hydrogen peroxide are not reactive in aqueous solutions and hence do not cause much 
damage in the body (Trenam, 1992).  However, it is noted that they can generate other 
species that are more harmful to the body.  In a process called the Fenton reaction, iron 
may act as a catalyst to produce ROS much more effectively than the above reaction.  
Free iron will react with hydrogen peroxide to yield a highly reactive hydroxyl free 
radical (    ). 
       
          
        ⁄     
      
            
           
These reactions do not effectively take place in vivo, but can be accelerated in the 
presence of iron.  Iron ion acts as a catalyst and form a perferryl species      -  
  or 
    -    intermediate when it reacts with superoxide radicals (  
 ).  This species then 
creates molecular oxygen as well as iron in ferrous state.  Ferrous iron then reacts with 
hydrogen peroxide and forms a hydroxyl radical (Trenam, 1992; Winterbourn, 1995). 
 
Mechanism of Liver Fibrosis 
Studies that have investigated HCV and PCT have concluded that both diseases 
can lead to fibrosis in the liver (Carpintero et al., 1997).  Of all patients who develop 
chronic hepatitis C, a quarter develops cirrhosis in 20 years, another quarter in 50 years; 
the remaining half does not experience in the progress in fibrosis in the liver.  To date 
there is no HCV-induced fibrogenesis mechanism that is confirmed.  It has been shown 
that an index that measures α2-macroglobulin, γ-globulin, heptoglobin, γ-GT 
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(glutamyltranspeptidase) and bilirubin can predict the presence of liver fibrosis 
(Schuppan al., 2002).  A study that investigated liver biopsies of HCV positive patients 
who were in different stages showed that there is a relationship between down-regulation 
of antioxidant proteins and later stages of liver fibrosis, which reinforces the relationship 
between the level of liver damage and oxidative stress (Ivanov et al., 2013).   
 There are several hypotheses to explain the pathogenesis of liver fibrogenesis, and 
one of them argues that various molecules, such as collagen I, are deposited in the 
extracellular matrix.  It is also proposed that ROS up-regulates the profibrogenic cytokine 
TGF-β (transforming growth factor-β) in hepatocytes and Kupffer cells in the liver 
(Bataller et al., 2005).  This is also confirmed by other reports that concluded that 
elevation in cytokines in liver and plasma has a clear correlation to the TGF1β and 
fibrosis score (Schuppan al., 2002).  HCV proteins, such as core, NS3/4A, NS4B, NS5A, 
trigger MAP kinase pathways that lead to the activation of NF-κB transcription factors 
and TGF1β expression (Ivanov et al., 2013).  Another molecule called osteopontin was 
discovered to play a large role in liver fibrosis as well.  The molecule is induced by 
phosphoinositol 3 kinase, NF-κB, and phosphokinase B pathway, and leads to the 
increased production of collagen I and suppression of matrix metalloproteinase (MMP) 
13, which alleviates scarring (Schuppan et al., 2002; Ivanov et al., 2013). 
The second proposed mechanism comes from the interaction between hepatic 
stellate cells (HSC) and apoptotic bodies of HCV-infected hepatocytes (Ivanov et al., 
2013).  HSC takes up the infected hepatocytes, which leads to expression of core or E2 
protein in the body, and leads to the production of TGF1β, connective tissue growth 
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factor (CTGF), collagen I as well as other profibrotic proteins.  HCV core and E2 protein 
has a secondary effect where it will suppress the expression of MMP-1, which is 
responsible for degradation of extracellular matrix.  The last mechanism of fibrogenesis 
is related to increased production of a particular type of proteoglycan called fibromodulin 
in HSC and hepatocytes.  In response to oxidative stress, fibromodulin promotes 
proliferation and migration of HSC in the liver (Ivanov et al., 2013). 
 
 
Iron Overload and Oxidative Stress In HCV and PCT 
Iron and HCV infection 
The direct relationship between iron and HCV infection is not very clear.  However, there 
are many proposed mechanisms and one of them which is shown figure 9, suggests that 
HCV stimulates the production of HDAC (histone deactylase) and CHOP (C/CBP 
homology protein), both directly and indirectly using ROS.  An increase in the 
concentration of those two molecules will lead to a decrease in C/EBP binding to the 
hepcidin gene promoter region which results in decreased hepcidin production.  The 
reduction in hepcidin production leads to increased absorption of iron from the small 
intestine leading to overload of iron in hepatocytes (Caballes et al., 2012). This process of 
decreased hepcidin leading to elevated iron absorption level which then decreases 
hepcidin level further, and enters a cyclical process of iron overload in the liver and the 
body. 
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Figure 9 – Pathogenesis of porphyria cutanea tarda. The figure shows several risk 
factors, such as presence of HCV infection or increased level of ROS, which may lower 
the activity level of UROD in hepatocytes leading to accumulation of porphyrins in the 
body. HCV and ROS elevate HDAC (histone deacetylase) and CHOP (C/CBP homology 
protein) levels, which then inhibits the binding of CEBP (CCAAT/enhancer-binding 
protein) to the promoter region of hepcidin. This, along with other factors such as HFE, 
HJV (hemojuvelin) and TfR2 mutations, lead to the decreased expression of hepcidin and 
increased iron absorption in the gut. (Figure taken from Caballes et al., 2012) 
 
 
There are many studies that evaluated the influence of iron on HCV replication, 
and it is still debatable what the direct effect is.  Some studies have found that iron 
stimulates HCV replication (Kakizaki et al., 2000), while others have shown that iron 
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suppresses HCV replication.  (Fillebeen et al., 2005; 2010) Still others have shown no 
relationship between iron concentration and the rate of HCV replication (Lehmann et al., 
2010).  What is clear is that HCV infection does lead to increased iron concentration in 
the liver and causes iron overload.  HCV can cause changes in iron homeostasis which 
then leads to development of liver fibrosis, insulin resistance, diabetes mellitus, porphyria 
cutanea tarda and HCC (Negro et al., 2009).  HCC mostly occurs when long-term HCV 
infection has caused cirrhosis in a patient (Tang et al., 2009). 
 
Oxidative Stress in HCV Infection 
As discussed above, iron generates hydroxyl and peroxide radicals via the Fenton 
reaction.  The body will experience oxidative stress when the concentration of free 
radicals goes up and the antioxidant capacity of the cells decreases.  Since iron is an 
important catalyst in the Fenton reaction and thus generation of ROS, it has been noted 
that an increase in iron probably leads to increased oxidative stress.  HCV infection and 
replication has been shown to increase the expression of TfR1 in the liver and decrease in 
hepcidin levels, thus increasing iron metabolism (Caballes et al., 2012). 
HCV uses several pathways to increase the concentration of ROS in the cell, and 
many HCV proteins are associated with the process.  HCV core protein leads to the 
dysregulation of mitochondria, which inhibits electron transport complex I activity.  This 
then results in increased production of ROS and increases the likelihood of apoptosis.  It 
has also been hypothesized that an increase in expression of prohibitin, which is a 
chaperone protein that interacts with mitochondrial respiratory complex IV, and affects 
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the mitochondrial process.  Core proteins are known to act directly on the mitochondrial 
outer membrane to dysregulate the organelle (Tang et al., 2009).  Other HCV proteins 
also contribute to the synthesis of ROS; when HCV proteins such as E1, E2 and NS4B 
are expressed, they can induce stress in endoplasmic reticulum by activating antioxidant 
defense Nrf2/ARE (Antioxidant Response Element).  This ultimately leads to increased 
production of hydrogen peroxide in the cells.  HCV has also shown indirectly induce 
oxidative stress in the cell by redistributing calcium ions between the endoplasmic 
reticulum, cytoplasm and mitochondria.  As it can be seen in figure 10, the core protein 
increases the activity of      uniporter.  Core protein also inhibits SERCA and NS5A 
lets the calcium ions leak leading to the movement of calcium ion from endoplasmic 
reticulum to the cytosol.  Increased concentration of intracellular calcium ion causes ROS 
production (Ivanov et al., 2013). 
Another mechanism that HCV uses to produce ROS is through the NADPH 
oxidase family, which includes Nox1 – 5, DUOX1 and DUOX2.  These seven NADPH 
oxidases are transmembrane enzymes that produce superoxide or hydrogen peroxide 
molecules via electron transport (Ivanov et al., 2013).  Nox1 and Nox4, in particular, 
contribute to the production of superoxide anion and hydrogen peroxide.  Nox4 is 
especially important because it is activated by TGFβ1 and produces those harmful species 
in the nucleus; oxidative species thus directly damage the DNA; and ultimately 
uncontrolled proliferation of the cell and cancer (Ivanov et al., 2013). 
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Figure 10 – The mechanism of oxidative stress that is induced in the cells infected 
with HCV (Figure taken from Ivanov et al., 2013) 
 
 
Another way eukaryotes mediate ROS is through the Nrf2 pathway (Petri et al., 
2012).  Nrf2 regulates human ARE which helps the cellular expression of antioxidant 
enzymes such as NAD(P)H:quinoneoxidoreductase 1 (NQO1).  The Nrf2 pathway is 
activated using several different pathways.  One of the earliest discoveries showed that 
Keap1 (Kelch-like associated protein 1), which is a protein that is anchored to the 
cytoskeleton of the cell, is an important regulator of Nrf2 activity (Petri et al., 2012).  
During normal conditions, Nrf2 is ubiquitinated by Keap1 and consequently degraded in 
the proteasome.  However, when there is a high concentration of electrophiles or ROS, 
Keap1 is inactivated and Nrf2 is stabilized (Ivanov et al., 2013).  The Keap1/Nrf2 
complex is regarded as an “oxidative stress sensor,” with the four cysteine residues on 
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Keap1 suggesting that Keap1 is the direct sensor. Oxidative stress level within the cell 
affects protein disulfide linkages and their rearrangement leads to the production of 
antioxidant chemicals (Petri et al., 2012). 
 
 
Figure 11 – The Keap1-Nrf2 system. Under normal conditions, Nrf2 is ubiquitinated by 
Keap1 and degraded. When Keap1 is inactivated due to oxidative stress or electrophiles, 
Nrf2 accumulates in the nucleus and activates cytoprotective genes. (Figure taken from 
Mitsuishi et al., 2012) 
 
 
Nrf 2 is dissociated from Keap1/Nrf2 complex, and goes into the nucleus to initiate the 
transcription of genes that will produce detoxifying antioxidant proteins including 
NAD(P)H:quinoneoxidoreductase 1, glutathione S-transferase, and heme oxygenase-1 
(Petri et al., 2012).  Nrf2 targets genes that are involved in the production of glutathione, 
drug excretion as well as NADPH synthesis (Petri et al., 2012).   
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Since the discovery of Keap1, other mechanisms that depend on kinase pathways 
and activate Nrf2 pathway have been discovered, such as mitogen-activated protein 
kinases (MAPK) and phosphatidylinositol-3 kinase pathways (Hybertson et al., 2011).  
Although earlier studies showed that Nrf2 can only be activated after reacting with 
cysteine residues of Keap1, it is clear that kinase signaling mechanisms are a critical part 
of the activation process of Nrf2 pathway (Hybertson et al., 2011). 
The Nrf2 pathway also increases glutathione synthesis.  Glutathione is a major 
antioxidant, which is concentrated in the liver.  Glutathione is a small thiol molecule that 
has a major function in oxidation-reduction reactions in animal cells. It is synthesized 
from glutamate, cysteine and glycine, which are catalyzed by two enzymes which are 
called glutamylcysteine synthetase and GSH synthetase.  It takes up free radicals and 
other ROS, such as hydroxyl radical, lipid peroxyl radical, peroxynitrite and hydrogen 
peroxide, both directly and indirectly (Wu et al., 2004).  When reacting with these species, 
GSH forms GSSG, which is the oxidized form of glutathione.  GSSG is then reduced to 
give GSH using NADPH-dependent glutathione reductase (Wu et al., 2004).  Patients 
with chronic HCV infection experience many symptoms that lead to decreased 
antioxidant activity in the body.  First of all, it reduces the overall glutathione 
concentration in the body.  It also increases the ratio between GSSG and GSH along with 
glutathione turnover.   
Suppression of hepcidin is mediated by ROS, and when ROS level is increased by 
many mechanisms that were discussed in the above section, it can lead to lowered 
production of hepcidin.  This causes an increase in iron metabolism and thus elevated 
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serum iron level. However, phlebotomy or dietary iron restriction has shown to decrease 
oxidative stress and lipid peroxidation in patients with chronic HCV infection (Ghany et 
al., 2009). 
 
Iron and ROS in PCT 
Elevated iron levels have been associated with PCT for many years, but the direct 
relationship between PCT and iron has not been established.  Iron does not inhibit UROD 
activity, but is necessary for inactivation of the enzyme.  In experiments performed on in 
vitro hepatocytes, iron facilitated the oxidation of uroporphyrinogen which can inhibit the 
decarboxylation process that is catalyzed by UROD (Phillips et al., 2001).  Therefore, 
iron can be seen to cause oxidative modification in uroporphyrinogen to alter the activity 
level of UROD, and accelerate the inhibition process by causing the accumulation of 
porphyrinogens.  Increased iron levels will also lead to elevation of ROS concentration in 
the body.  The ROS creates uroporphyrin and non-porphyrin products including 
uroporphomethene from uroporophyrinogen. This then leads to the accumulation of 
uroporphyrinogen in the skin, and physical manifestation of the symptoms when it is 
exposed to UV rays.   
Depletion of excess iron storage using phlebotomy is an effective method in 
managing PCT.  Lowered serum iron level quickly induces the remission of cutaneous 
lesions and symptoms that are normally present on the skin.  UROD activity level goes 
up gradually in patients with sPCT, and many of them improved in the next several years 
after phlebotomy.  On the other hand, patients with fPCT did not experience an increase 
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in UROD activity in hepatocytes even though many of them improved clinically.  Despite 
the fact that the relationship between PCT and iron overload is not clear, one thing that is 
evident is that symptoms of the disease manifest themselves at the presence of multiple 
risk factors. 
 
Relationship between Chronic HCV infection and PCT 
It is clear from many studies that there is a strong association between HCV 
infection and PCT.  It has been demonstrated that as many as 50% of PCT patients have 
chronic HCV infection (Gisbert, 2003).  Other studies suggest that patients with HCV 
infections usually develop PCT at an earlier age than others who do not have the 
infection.  However, it is not altogether clear whether the virus itself is involved in the 
pathogenesis of PCT and contributes to the symptoms.  It is common for patients with 
PCT to experience iron overload, and the removal of iron from the body prevents 
porphyrin overproduction and the symptoms.  When iron is administered and serum iron 
level returns to normal, patients usually see a relapse in PCT.  Since patients with PCT 
and HCV experience elevated iron concentration in the liver, and iron is one of the 
triggering factors in both diseases, it may act as one of the key factors that connect the 
two liver diseases.   
Conclusion 
 The exact relationship between HCV infection and PCT has not been discovered, 
but it is clear that iron overload is one of the major factors that contribute to the 
development and propagation of both diseases. Iron overload leads to build up of ROS, 
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which then leads to increased risk of both diseases; this is especially true in the case of 
PCT as ROS decreases UROD activity levels. However, as research on the prevalence of 
the two diseases has suggested, there is no direct link between the populations of patients 
who suffer from HCV infection and PCT. Furthermore, studies on PCT revealed that 
there are many risk factors which must be present for the disease to be manifested; 
therefore, it is reasonable to conclude that the two diseases are not directly related. 
Instead, it may be that HCV infection causes PCT when other risk factors are present as 
well. The relationship between HCV infection and PCT will continue to be evaluated as 
further research identifies the causes and the mechanism behind the two diseases. 
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